CytoDyn Stock Price, News & Analysis (OTCMKTS:CYDY)

$0.61 0.02 (3.40 %)
(As of 11/17/2017 06:59 AM ET)
Previous Close$0.58
Today's Range$0.57 - $0.61
52-Week Range$0.46 - $0.84
Volume71,795 shs
Average Volume167,540 shs
Market Capitalization$98.74 million
P/E RatioN/A
Dividend YieldN/A
Beta0.57

About CytoDyn (OTCMKTS:CYDY)

CytoDyn logoCytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the clinical development and commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The Company's lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells. The Company's product pipeline also includes Cytolin and CytoFeline. Cytolin is a mouse monoclonal antibody developed to identify a specific type of immune cell called a cytotoxic T cell, or cytotoxic T lymphocyte (CTL). CytoFeline is an anti-lymphocyte function-associated antigen-1 (LFA-1) antibody for the treatment of Feline Immunodeficiency Virus (FIV) infection. PRO 140 blocks HIV from entering a cell by binding to a molecule called C-C chemokine receptor type 5 (CCR5). The Company has finished Phase II clinical trials for PRO 140 with demonstrated antiviral activity in man.


Industry, Sector and Symbol:
  • Industry: N/A
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: OTCMKTS:CYDY
  • Previous Symbol: NASDAQ:CYDY
  • CUSIP: N/A
  • Web: www.cytodyn.com
Debt:
  • Current Ratio: 0.39%
  • Quick Ratio: 0.39%
Sales & Book Value:
  • Annual Sales: N/A
  • Price / Sales: N/A
  • Book Value: ($0.01) per share
  • Price / Book: -60.90
Profitability:
  • Trailing EPS: ($0.22)
  • Net Income: ($25,760,000.00)
  • Return on Equity: -10,003.02%
  • Return on Assets: -298.36%
Misc:
  • Employees: 146
  • Outstanding Shares: 160,380,000
 

Frequently Asked Questions for CytoDyn (OTCMKTS:CYDY)

What is CytoDyn's stock symbol?

CytoDyn trades on the OTCMKTS under the ticker symbol "CYDY."

How were CytoDyn's earnings last quarter?

CytoDyn Inc. (OTCMKTS:CYDY) released its earnings results on Tuesday, October, 10th. The biotechnology company reported ($0.08) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.05) by $0.03. View CytoDyn's Earnings History.

When will CytoDyn make its next earnings announcement?

CytoDyn is scheduled to release their next quarterly earnings announcement on Friday, January, 12th 2018. View Earnings Estimates for CytoDyn.

Where is CytoDyn's stock going? Where will CytoDyn's stock price be in 2017?

1 brokerages have issued 12-month price targets for CytoDyn's stock. Their forecasts range from $2.00 to $2.00. On average, they expect CytoDyn's share price to reach $2.00 in the next twelve months. View Analyst Ratings for CytoDyn.

Who are some of CytoDyn's key competitors?

Who are CytoDyn's key executives?

CytoDyn's management team includes the folowing people:

  • Anthony D. Caracciolo, Independent Chairman of the Board (Age 60)
  • Nader Z. Pourhassan Ph.D., President, Chief Executive Officer, Director (Age 52)
  • Michael D. Mulholland, Chief Financial Officer, Treasurer, Corporate Secretary (Age 63)
  • Denis R. Burger Ph.D., Director (Age 70)
  • Carl C. Dockery, Director (Age 52)
  • Gregory A. Gould CPA, Independent Director (Age 50)
  • A. Bruce Montgomery M.D., Independent Director (Age 63)
  • Jordan G. Naydenov, Independent Director (Age 54)

How do I buy CytoDyn stock?

Shares of CytoDyn can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CytoDyn's stock price today?

One share of CytoDyn stock can currently be purchased for approximately $0.61.

How big of a company is CytoDyn?

CytoDyn has a market capitalization of $98.74 million. The biotechnology company earns ($25,760,000.00) in net income (profit) each year or ($0.22) on an earnings per share basis. CytoDyn employs 146 workers across the globe.

How can I contact CytoDyn?

CytoDyn's mailing address is 1111 Main St Ste 660, VANCOUVER, WA 98660-2970, United States. The biotechnology company can be reached via phone at +1-360-9808524 or via email at [email protected]


MarketBeat Community Rating for CytoDyn (OTCMKTS CYDY)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  41 (Vote Outperform)
Underperform Votes:  58 (Vote Underperform)
Total Votes:  99
MarketBeat's community ratings are surveys of what our community members think about CytoDyn and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for CytoDyn (OTCMKTS:CYDY)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 1 Buy Rating, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $2.00

Consensus Price Target History for CytoDyn (OTCMKTS:CYDY)

Price Target History for CytoDyn (OTCMKTS:CYDY)

Analysts' Ratings History for CytoDyn (OTCMKTS:CYDY)

Show:
DateFirmActionRatingPrice TargetDetails
8/10/2017HC WainwrightSet Price TargetBuy$2.00View Rating Details
10/6/2016Rodman & RenshawInitiated CoverageBuy$1.60View Rating Details
(Data available from 11/18/2015 forward)

Earnings

Earnings History and Estimates Chart for CytoDyn (OTCMKTS:CYDY)

Earnings by Quarter for CytoDyn (OTCMKTS:CYDY)

Earnings History by Quarter for CytoDyn (OTCMKTS CYDY)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/12/2018        
10/10/2017Q1 2018($0.05)($0.08)ViewN/AView Earnings Details
10/12/2016Q1($0.05)($0.04)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for CytoDyn (OTCMKTS:CYDY)
Current Year EPS Consensus Estimate: $-0.17 EPS

Dividends

Dividend History for CytoDyn (OTCMKTS:CYDY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for CytoDyn (OTCMKTS CYDY)

Insider Ownership Percentage: 15.30%
Institutional Ownership Percentage: 0.15%
Insider Trades by Quarter for CytoDyn (OTCMKTS:CYDY)

Insider Trades by Quarter for CytoDyn (OTCMKTS CYDY)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/21/2016Nader PourhassanInsiderBuy15,000$0.66$9,900.00View SEC Filing  
10/17/2016Michael D MulhollandCFOBuy11,000$0.66$7,260.00View SEC Filing  
10/30/2014Anthony CaraccioloDirectorBuy26,000$0.72$18,720.00View SEC Filing  
10/15/2014Michael D MulhollandCFOBuy2,500$0.79$1,975.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for CytoDyn (OTCMKTS:CYDY)

Latest Headlines for CytoDyn (OTCMKTS CYDY)

Source:
DateHeadline
CytoDyn’s PRO 140 Monoclonal Antibody Prevents Graft-Versus-Host Disease in Model of Bone Marrow Stem Cell TransplantationCytoDyn’s PRO 140 Monoclonal Antibody Prevents Graft-Versus-Host Disease in Model of Bone Marrow Stem Cell Transplantation
finance.yahoo.com - November 14 at 6:10 PM
CytoDyns Two-Year Update on Its PRO 140 Monotherapy Study in HIV Accepted at CROI 2017 - GlobeNewswire (press release)CytoDyn's Two-Year Update on Its PRO 140 Monotherapy Study in HIV Accepted at CROI 2017 - GlobeNewswire (press release)
globenewswire.com - November 17 at 8:48 AM
CytoDyn Files Protocol for Extended Access to PRO 140 for Patients Who Reach the End of PRO 140 Pivotal Phase 3 ... - GlobeNewswire (press release)CytoDyn Files Protocol for Extended Access to PRO 140 for Patients Who Reach the End of PRO 140 Pivotal Phase 3 ... - GlobeNewswire (press release)
globenewswire.com - October 24 at 9:45 AM
SeeThruEquity Issues Update on CytoDyn Inc. (CYDY) and Raises Target to $3.75 - Baystreet.caSeeThruEquity Issues Update on CytoDyn Inc. (CYDY) and Raises Target to $3.75 - Baystreet.ca
www.baystreet.ca - October 21 at 4:34 PM
CYTODYN INC. Files SEC form 10-Q, Quarterly ReportCYTODYN INC. Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - October 12 at 4:47 PM
Coherus Neulasta Biosimilar At FDA Altar, CytoDyn On Fast Track, VIVE Abuzz - NasdaqCoherus' Neulasta Biosimilar At FDA Altar, CytoDyn On Fast Track, VIVE Abuzz - Nasdaq
www.nasdaq.com - October 7 at 4:28 PM
CytoDyn Announces Favorable Protocol Modifications for Pivotal Phase 3 Combination Trial With PRO 140 After ... - GlobeNewswire (press release)CytoDyn Announces Favorable Protocol Modifications for Pivotal Phase 3 Combination Trial With PRO 140 After ... - GlobeNewswire (press release)
globenewswire.com - October 6 at 10:04 AM
CytoDyn inks $9M direct equity offering; shares off 16% - Seeking AlphaCytoDyn inks $9M direct equity offering; shares off 16% - Seeking Alpha
seekingalpha.com - September 12 at 4:21 PM
CytoDyn Announces $10.0 Million Registered Direct Offering - GlobeNewswire (press release)CytoDyn Announces $10.0 Million Registered Direct Offering - GlobeNewswire (press release)
globenewswire.com - September 12 at 4:21 PM
CYTODYN INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and ECYTODYN INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and E
biz.yahoo.com - September 12 at 9:25 AM
CytoDyn to Present at Rodman & Renshaw Global Investment Conference on September 12 - GlobeNewswire (press release)CytoDyn to Present at Rodman & Renshaw Global Investment Conference on September 12 - GlobeNewswire (press release)
globenewswire.com - September 8 at 8:20 AM

Social Media

Financials

Chart

CytoDyn (OTCMKTS CYDY) Chart for Saturday, November, 18, 2017
Loading chart…

This page was last updated on 11/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.